Pre- and post-transplant treatment of hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue SUPPL. MAY, 2000, Pages

  Gane, Edward ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; OKT 3; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; GRAFT REJECTION; GRAFT SURVIVAL; HEMOLYSIS; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE DEFICIENCY; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LIVER TRANSPLANTATION; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; RECURRENT INFECTION;

EID: 0033920186     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02125.x     Document Type: Conference Paper

References (83)

1. Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med. 1996; 334: 821-7.
2. Weinstein J, Poterucha J, Zein N, Wiesner R, Persing DH, Rakela J. Epidemiology and natural history of hepatitis C infection in liver transplant recipients. J. Hepatol. 1995; 22: 154-9.
3. Casavilla A, Mateo R, Rakela J et al. Impact of hepatitis C virus on survival following primary liver transplantation under FK506. Hepatology 1994; 20: 133A.
4. Feray C, Caccamo L, Gugenheim J et al. and EUROHEP group. HCV and liver transplantation: preliminary results of a European multicentric study. Hepatology 1996; 24: 510A.
5. Boker KH, Dalley G, Bahr MJ et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997; 25: 203-10.
6. Sheiner PA, Schugler L, Emre S, Thung S, Lau JYN, Guy SR. Retransplantation for recurrent hepatitis C. Liver Transplant. Surg. 1997; 3: 130-6.
7. Mathurin P, Mouquet C, Poynard T et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-63.
8. National Institutes of Health. Consensus document on the management of chronic hepatitis C. Hepatology 1997; 26: 2-11S.
9. Wright HGJ, Van Thiel D. Preliminary experience with alpha 2-b interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992; 53: 121-4.
10. Wright T, Combs C, Kim M et al. Interferon-α therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 773-9.
11. Feray C, Samuel D, Gigou M, Paradis V, Reynes M, Bismuth H. An open trial of interferon-α recombinant for hepatitis C after liver transplantation. Hepatology 1995; 22: 1084-9.
12. Gane E, Lo SK, Portmann BC et al. A randomised study comparing ribavirin and interferon-alpha monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27: 1403-7.
13. Hanafusa T, Ichikawa Y, Kishikawa H et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant recipients over 20 years. Transplantation 1998; 66: 471-6.
14. Durlik M, Gaciong Z, Roewinska D et al. Long-term results of treatment of chronic hepatitis B and C with interferon in renal allograft recipients. Transplant. Int. 1998; 11: S135-9.
15. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant alpha 2b interferon in kidney transplant recipients. Transplantation 1995; 59: 1426-31.
16. Izopet J, Rostaing L, Moussion F et al. High rate of hepatitis C clearance in haemodialysis patients after interferon therapy. J. Infect. Dis. 1997; 176: 1614-17.
17. Pol S, Thiers V, Carnot F et al. Efficacy and tolerance of interferon therapy on HCV infection in haemodialysed patients. Kidney Int. 1995; 47: 1412-8.
18. Hanroutel-Saliou C, Brodard V, Toupance O et al. One year interferon therapy in patients with chronic hepatitis C undergoing haemodialysis. J. Ma Soc. Nephrol. 1997; 9: A900.
19. Hirsch MS, Tolkoff-Rubin NE, Kelly AP, Rubin RH. Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis. J. Infect. Dis. 1983; 148: 335.
20. Slater A, Klein J, Sonnerfield G et al. The effects of interferon in a model of rat heart transplantation. J. Heart Lung Transplant. 1992; 11: 975-8.
21. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 512-16.
22. Kramer P, ten Kate FW, Bijnen AB, Jeekel J, Weimar W Recombinant leucocyte interferon induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1: 989-90.
23. Jain A, Demetris A, Manez R et al. Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transplant. Surg. 1998; 4: 197-203.
24. Garnier JL, Chevallier P, Dubernard JM, Trepo C, Touraine JL, Chossegros P. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant. Proc. 1997; 29: 783.
25. Cattral MS, Hemming A, Wanless IR et al. Outcome of longterm ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Transplantation 1999; 67: 1277-80.
26. Gane E, Tibbs C, Ramage J, Portmann B, Williams R. Ribavirin therapy for hepatitis C infection following liver transplantation. Transplant. Int. 1995; 8: 61-4.
27. Feray C, Roche B, Dussaix E et al. An open trial of ribavirin in chronic HCV infection after liver transplantation. Hepatology 1997; 24: A.
28. Di Bisceglie A, Shindo M, Pong TL et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649-54.
29. Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi YA. pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993; 105: 507-12.
30. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058-61.
31. Bodenheimer HC, Lindsay KL, Lewis JH, Thung SN, Seef LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicentre trial. Hepatology 1997; 26: 473-7.
32. Di Bisceglie AM, Conjeevaram HA, Fried MW et al. Ribavirin as therapy for chronic hepatitis C. Ann. Intern. Med. 1995; 123: 897-903.
33. Zeuzem S, Schmidt JM, Lee J-H, von Wagner M, Teuber G, Roth WK. Hepatitis C dynamics in vivo: effect of ribavirin and interferon-α on viral turnover. Hepatology 1998; 26.
34. Lee J, Wagner M, Roth W et al. Effect of ribavirin on viral load and quasispecies distribution in patients infected with hepatitis C virus. J. Hepatol. 1998; 29: 29-35.
35. Ilyin GP, Langouët S, Rissel M, Delcros J-G, Guillouzo A, Guguen-Guillouzo C. Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes. Hepatology 1998; 27: 1687-94.
36. Brann OS, McHutchinson JG. The effect of combination therapy on peripheral blood lymphocyte and leucocyte counts. Hepatology 1998; 26.
37. Ning Q, Brown D, Parodo J et al. Ribavarin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1, the procoagulant fg12 prothrombinase and preserves Th1 cytokine production, but inhibits Th2 cytokine response. J. Immunol. 1998; 160: 3487-93.
38. Safadi R, Shouval D, Kaspa RT, Ashur Y, Ilan Y. Beneficial effect of ribavirin on hepatitis C-associated cryoglobulinemia after liver transplantation. Liver Transplant. Surg. 1996; 2: 263-8.
39. Gane E, Maertens G, Ducatteeuw A et al. Antibodies to hepatitis C virus envelope proteins correlate with hepatitis C viraemia after liver transplantation. Transplantation 1999; 67: 78-84.
40. Jolley W, Sharma B, Chami R, Ng C, Bullington R. Long term skin allograft survival by combined therapy with suboptimal dose of cyclosporin and ribavirin. Transplant. Proc. 1988; 20: 703-6.
41. McHutchinson J, Gordon S, Schiff E et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998; 339: 1485-92.
42. Poynard T, Marcellin P, Lee S et al. Randomised trial of interferon α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α-2b plus placebo for 48 weeks. Lancet 1998; 352: 1426-32.
43. Bizollon T, Palazzo U, Ducerf C et al. Pilot study of combination of Interferon alpha and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26: 500-4.
44. Thevenot T, Mathurin P, Moussalli J et al. Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin. J. Viral Hepatitis 1997; 4: 243-53.
45. Dodson S, Vargas H, Shakil O et al. Final analysis of ribavirin and alpha-interferon for the treatment of hepatitis C infection after liver transplantation. Hepatology 1998; 28: 262A.
46. Bellati G, Alberti A, Belli L et al. Therapy of chronic hepatitis C after liver transplantation: multicentre Italian experience. J. Hepatol. 1999; 27: GS1.
47. Lavezzo B, Leone N, Smedlie A et al. Combination therapy of interferon and ribavirin for recurrent hepatitis C after liver transplantation. J. Hepatol. 1999; 27: WP4.
48. Lampertico P, Rumi I, Romeo R. A multicentre randomised controlled trial of recombinant interferon alpha 2b in patients with acute transfusion associated hepatitis C. Hepatology 1994; 19: 19-22.
49. Caronia S, Coleman N, Wight DGD, Petrick J, Gimson A, Alexander GJM. Retransplantation for grafts damaged by hepatitis C. In: Proceedings of BASL, London, September 1997.
50. Doughty AL, Spencer JD, Cossart YE, McCaughan GW. Cholestatic hepatitis post liver transplant is associated with persistingly high serum hepatitis C virus RNA levels. Liver Transplant. Surg. 1998; 4: 15-21.
51. Gane E, Naoumov N, Qian K et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-77.
52. Lim H, Lau G, Davis G, Dolson D. Cholestatic hepatitis leading to hepatic failure in a pateint with organ-transmitted HCV infection. Gastroenterology 1994; 106: 248-51.
53. Rosen HR, Shackleton CR, Higa L et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation Am. J Gastroenterol. 1997; 92: 1453-7.
54. Delladetsima J, Boletis J, Makris F, Psichogiou M, Kostakis A, Hatzakis A. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C infection. Liver Transplant. Surg. 1999; 5: 294-300.
55. Telegdy L, Gorog D, Horanyi M. Severe reactivation of HCV hepatitis after liver transplantation: successful treatment with interferon/ribavirin. J. Hepatol. 1999; 27: C156.
56. Dickson RC, Caldwell SH, Ishitani MB, Lau JYN, Driscoll CJ, Stevenson WC. Clinical and histologic patterns in early graft failure due to recurrent hepatitis C infection after liver transplantation. Transplantation 1996; 61: 701-5.
57. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med. 1993; 329: 1842-7.
58. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-15.
59. Markowitz J, Martin P, Conrad A et al. Prophylaxis against HBV recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-9.
60. Charlton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-30.
61. Sata M, Noguchi S, Suzuki H et al. Interferon prevents chronicity of acute hepatitis C transmitted by accidental needlestick. Hepatology 1996; 24: 573A.
62. Christie J, Healey C, Watson J et al. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C. 2 year follow up. Clin. Exp Immunol. 1997; 110: 4-8.
63. Reddy KR, Weppler D, Zervbos XA et al. Recurrent HCV infection following OLT. the role of early interferon treatment. Hepatology 1996; 24: 295A.
64. Singh N, Gayowski T, Wannstedt C et al. Interferon-α for prophylaxis of recurrent viral hepatitis C in liver transplant recipients. Transplantation 1998; 65: 82-6.
65. Sheiner P, Boros P, Klion F et al. The efficacy of prophylactic interferon-α in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831-8.
66. Mazzaferro V, Regalia E, Pulvirenti A et al. Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. Transplant. Proc. 1997; 29: 519-21.
67. Krawczynski K, Fattom A, Spelbring J et al. Early termination of HCV infection by passive anti-HCV transfer in experimentally infected chimpanzees. Hepatology 1998; 28.
68. Feray C, Samuel D, Gigou M, Reynès M, Bismuth H. Reduced incidence of recurrent and acquired infection by HCV after liver transplantation in patients receiving immunoglobulins. Hepatology 1994; 20: 131A.
69. Lau JYN, Davis GL, Brunson ME et al. Hepatitis C virus infection in kidney transplant recipients. Hepatology 1993; 18: 1027-31.
70. Bjoro K, Froland S, Yun Z, Samdal H, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinaemia after treatment with contaminated immune globulin. N. Engl. J. Med. 1994; 331: 1607-11.
71. Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol. 1997; 26: 1-5.
72. Magrin S, Craxi A, Fabiano C et al. Hepatitis C viraemia in chronic liver disease: relationship to interferon-α or corticosteroid treatment. Hepatology 1994; 19: 273-9.
73. McHutchinson JG, Wilkes LB, Pockros PJ et al. Pulse corticosteroid therapy increases viraemia (HCV RNA) in patients with chronic HCV infection. Hepatology 1993; 18: 87A.
74. Sheiner PA, Schwartz ME, Mor E et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30-4.
75. Singh N, Gayowski T, Ndimbie OK, Nedjar S, Wagener MM, Yu VL. Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: association with rejection and increased immunosuppression after transplantation. Surgery 1996; 19: 452-6.
76. Rosen HR, Shackleton CR, Higa L et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation Am. J Gastroenterol. 1997; 92: 1453-7.
77. Tisone G, Angelico M, Palmieri G et al. A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation 1999; 67: 1308-13.
78. Kakumu S, Takayanagi M, Iwata K et al. Cyclosporine therapy affects aminotransferase activity but not HCV RNA levels in chronic hepatitis C. J. Gastroenterol. Hepatol. 1997; 12: 62-6.
79. Mulligan DC, Goldstein RM, Levy MF. Hepatitis C virus infection in liver transplantation: effect of cyclosporine A versus FK506 (Abstract). Am. Soc. Transplant Phys. Annual Meeting 1995.
80. Zervos XA, Weppler D, Fragulidis GP et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998; 65: 1044-6.
81. The US Multicentre FK506 Liver Study group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N. Engl. J. Med. 1994; 331: 1110-15.
82. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft recipients. Lancet 1994; 344: 423-8.
83. Platz K, Mueller C, Willimski C et al. Indication for mycophenylate mofetil therapy in hepatitis C patients undergoing liver transplantation. Transplant. Proc. 1998; 30: 2232-3.